CA3017758A1 - Methods of treating or preventing graft versus host disease - Google Patents

Methods of treating or preventing graft versus host disease Download PDF

Info

Publication number
CA3017758A1
CA3017758A1 CA3017758A CA3017758A CA3017758A1 CA 3017758 A1 CA3017758 A1 CA 3017758A1 CA 3017758 A CA3017758 A CA 3017758A CA 3017758 A CA3017758 A CA 3017758A CA 3017758 A1 CA3017758 A1 CA 3017758A1
Authority
CA
Canada
Prior art keywords
antibody
seq
humanized antibody
gvhd
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017758A
Other languages
English (en)
French (fr)
Inventor
Jessica A. SACHS
John E. Ford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA3017758A1 publication Critical patent/CA3017758A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3017758A 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease Pending CA3017758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US62/307,896 2016-03-14
US201662420825P 2016-11-11 2016-11-11
US62/420,825 2016-11-11
PCT/US2017/022067 WO2017160700A1 (en) 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease

Publications (1)

Publication Number Publication Date
CA3017758A1 true CA3017758A1 (en) 2017-09-21

Family

ID=58455657

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017758A Pending CA3017758A1 (en) 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease

Country Status (12)

Country Link
US (1) US20190077868A1 (https=)
EP (1) EP3430053A1 (https=)
JP (3) JP2019512493A (https=)
KR (2) KR102667332B1 (https=)
CN (2) CN117298268A (https=)
AU (2) AU2017234010B2 (https=)
BR (1) BR112018068625A2 (https=)
CA (1) CA3017758A1 (https=)
IL (1) IL261767A (https=)
MA (1) MA43755A (https=)
MX (2) MX2018011025A (https=)
WO (1) WO2017160700A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
CN109414502A (zh) 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
BR112019022268A2 (pt) * 2017-04-28 2020-05-19 Millennium Pharmaceuticals, Inc. método para o tratamento de distúrbios pediátricos
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CN115137752A (zh) * 2015-08-25 2022-10-04 Uab研究基金会 用于干细胞移植的方法
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease

Also Published As

Publication number Publication date
JP2022137024A (ja) 2022-09-21
CN117298268A (zh) 2023-12-29
US20190077868A1 (en) 2019-03-14
MX2018011025A (es) 2019-01-10
MX2024008740A (es) 2024-07-23
WO2017160700A1 (en) 2017-09-21
EP3430053A1 (en) 2019-01-23
AU2017234010B2 (en) 2024-06-13
MA43755A (fr) 2018-11-28
JP2025118642A (ja) 2025-08-13
AU2024203289A1 (en) 2024-08-01
KR102667332B1 (ko) 2024-05-20
AU2017234010A1 (en) 2018-09-27
KR20240074903A (ko) 2024-05-28
KR20180117195A (ko) 2018-10-26
JP2019512493A (ja) 2019-05-16
IL261767A (en) 2018-10-31
KR102830639B1 (ko) 2025-07-07
BR112018068625A2 (pt) 2019-07-30
CN109153721A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
US11884731B2 (en) Vedolizumab for the treatment of fistulizing Crohn's disease
JP7474287B2 (ja) 炎症性腸疾患の治療を目的とする三剤併用療法
AU2017234009B2 (en) Method of preventing graft versus host disease
AU2024203289A1 (en) Methods of treating or preventing graft versus host disease
US20190194333A1 (en) Klrg1 depletion therapy
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
CZ20032672A3 (cs) CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"
WO2026080575A1 (en) Anti-cd38 antibodies and their uses
KR20250087734A (ko) T-림프구 매개 질환의 치료 방법
CN101015693A (zh) Cd25结合分子在类固醇耐受型患者中的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220310

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240806

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250605

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260226

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260316